(Alliance News) - Stocks in London are called higher, as investors shrug off nerves ahead of a key US inflation reading. Eyes are firmly on Wednesday's consumer price index data at 1330 BST. This is ...

(Alliance News) - Stocks in London are set to open higher on Wednesday, ahead of a key inflation reading from the US. IG says futures indicate the FTSE 100 to open up 43.9 points, 0.5%, at 8,472.03 on ...

(Alliance News) - A consortium of investors, including Blackstone Inc and Thomson Reuters, on Tuesday said they plan to sell shares worth just short of GBP1.6 billion in London Stock Exchange Group ...

Under the updated proposals, the limits on the cash exit under the scheme and the HEFT tender offer have been increased to 15% from 5% of each company's issued share capital. In addition, the pair's ...

Headlam Group PLC - Birmingham-based floor coverings company - Warns will report a "significant" pretax loss in the first half on a double-digit revenue decline. Says revenue in the four months to ...

The decision – which drew a fiery response from Beijing – comes as President Joe Biden gears up for a re-run of his 2020 contest with Republican rival Donald Trump in November's election, with ...

(Alliance News) - Vodafone PLC on Tuesday reported a return to growth in Germany, as it delivered full-year results slightly ahead of its expectations. Shares in Vodafone rose 2.5% to 71.72 pence in ...

Huw Pill, the bank's chief economist, told an online event organised by the accountancy body ICAEW that the bank could consider cutting rates if inflation continues to ease off.

DCC PLC on Tuesday declared a higher annual dividend despite a slight decline in profit, noting this marked 30 consecutive years of increased payouts. DCC shares were down 4.9% to 5,615.00 pence early ...

The Gloucester, England-based social housing and maintenance service company is a leading provider to the UK housing sector. Its latest 12 year contract to provide services to North Lanarkshire ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Hutchmed has also initiated a phase II/III trial of the combination of its Surufatinib treatment with Jiangsu Hengrui Pharmaceuticals Co Ltd's Camrelizumab in patients with metastatic pancreatic ...